Hormone-refractory prostate cancer: an evolving standard of care.
The treatment of advanced prostate cancer has evolved rapidly in the last several years. Therapeutic options for patients with advanced disease, once limited to the use of androgen deprivation, have expanded to include a number of interventions, including secondary hormonal manipulations, chemotherapy, and a variety of investigational approaches.
Small
E J
EJ
University of California, San Francisco Comprehensive Cancer Center, 94115, USA.
Reese
D M
DM
Vogelzang
N J
NJ
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000628:therapy*; D043823:Taxoids
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel